Observational Prospective Study Describing the Global Patient Care and Follow-up of Prostate Cancer Patients Treated With Degarelix (DUO)
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 10 Oct 2018
At a glance
- Drugs Degarelix (Primary)
- Indications Prostate cancer
- Focus Adverse reactions
- Acronyms DUO
- Sponsors Ferring Pharmaceuticals
- 02 Oct 2018 Planned End Date changed from 30 Dec 2018 to 31 Jan 2019.
- 02 Aug 2018 Status changed from recruiting to active, no longer recruiting.
- 06 Oct 2017 Planned End Date changed from 30 Nov 2018 to 30 Dec 2018.